Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Nebuliser hygiene in cystic fibrosis: evidence-based recommendations

Jane Bell, Lauren Alexander, Jane Carson, Amanda Crossan, John McCaughan, Hazel Mills, Damian O'Neill, John E. Moore, B. Cherie Millar on behalf of the Northern Ireland Working Group on Nebuliser Care and Hygiene in Cystic Fibrosis
Breathe 2020 16: 190328; DOI: 10.1183/20734735.0328-2019
Jane Bell
1Northern Ireland Paediatric Cystic Fibrosis Centre, Dept of Physiotherapy, Royal Belfast Hospital for Sick Children, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Alexander
1Northern Ireland Paediatric Cystic Fibrosis Centre, Dept of Physiotherapy, Royal Belfast Hospital for Sick Children, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Carson
1Northern Ireland Paediatric Cystic Fibrosis Centre, Dept of Physiotherapy, Royal Belfast Hospital for Sick Children, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Crossan
2Northern Ireland Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John McCaughan
3Dept of Medical Microbiology, Royal Victoria Hospital, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hazel Mills
1Northern Ireland Paediatric Cystic Fibrosis Centre, Dept of Physiotherapy, Royal Belfast Hospital for Sick Children, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damian O'Neill
2Northern Ireland Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John E. Moore
2Northern Ireland Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
4Northern Ireland Public Health Laboratory, Dept of Bacteriology, Belfast City Hospital, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Cherie Millar
2Northern Ireland Regional Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
4Northern Ireland Public Health Laboratory, Dept of Bacteriology, Belfast City Hospital, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bcmillar@niphl.dnet.co.uk
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Nebulised therapies are extensively used in the daily therapeutic management of cystic fibrosis both for mucociliary clearance and for the management of chronic infections. Extensive developments have been made in relation to nebulised drug delivery mechanisms and drug formulations, and guidelines have been prepared that have addressed the appropriate use of such therapies. However, due to these developments, a plethora of nebuliser devices and drug chambers exist, and frequently, the limited guidance provided in relation to nebuliser hygiene is to follow manufacturers' instructions. Such instructions are inconsistent and at times confusing, translating to an increase in the burden associated with nebuliser maintenance. An evidence-based universal guideline relating to nebuliser care and hygiene is urgently required that is applicable to both at-home use and inpatient use. This article reviews the scientific literature in order to propose an evidence-based approach to nebuliser hygiene to ensure optimum drug delivery, and infection prevention and control.

Educational aims

  • To understand the reasons why nebuliser hygiene is important.

  • To give an overview of the current nebuliser care instructions that have been described by manufacturers, societies and the scientific literature.

  • To outline the current nebuliser hygiene practices used by persons with cystic fibrosis in the home and hospital settings.

  • To highlight areas that need further evaluation to promote optimum nebuliser care.

  • To establish an evidence-based guideline for nebuliser hygiene in relation to cystic fibrosis.

Abstract

Current nebuliser hygiene practice is varied and challenging at home and in hospital. This review of the scientific literature proposes an evidence-based approach to nebuliser hygiene to ensure optimum drug delivery and infection prevention and control. https://bit.ly/3b9jGee

Choice of nebuliser device used in the therapy of patients with cystic fibrosis (CF) is dictated by the presence of clinical efficacy studies, device specifications, drug dosage and individual patient characteristics, meaning that not all patients can use the same nebuliser parts. Indeed, several different nebulisers may be required for use over time in the case of a single patient [1, 2]. Due to the variety of nebulisers used, the manufacturers' advice is differing and often conflicting. Both the European Respiratory Society “Guidelines on the use of nebulisers” [3] and the British Thoracic Society “Guidelines for non-CF bronchiectasis” [4] recognise that the ideal standards and methods have not been established, and that a universal code of practice should be produced for the maintenance of nebuliser equipment. Although this code of best practice has not yet been generated, following manufacturers' instructions, as well as local infection and prevention control policies, are generally recommended.

Sources of information

A search of peer-reviewed scientific literature was performed. PubMed, Web of Science and the Cochrane Library were searched for studies evaluating microbial contamination, nebuliser hygiene, cleaning and disinfection methods. Searches were performed and all articles published since 1985 in English were initially considered (figure S1). Guidelines published by cystic fibrosis, lung and respiratory societies were also examined as well as manufacturers' guidelines of the main nebuliser units and drug chambers used within the CF community in the UK (tables S1 and S2). The articles selected for inclusion of this review article specifically contained evidence to reliably inform the recommendations contained in this article, relating to nebuliser hygiene.

Definitions of key terms

A table of key terms and definitions is detailed in table 1, explaining the various terminologies used throughout this review.

View this table:
  • View inline
  • View popup
Table 1

Key terms and definitions

Why is there a need to clean and disinfect nebulisers?

Nebuliser performance

Nebuliser maintenance plays an important role in terms of performance, particularly in the case of electronic vibrating mesh nebulisers such as the e-Flow Rapid (Pari, Byfleet, UK). Such nebulisers offer several advantages particularly in terms of improved delivery of specific drug doses at target specific sites and a reduction in nebulisation time with less attributed mechanical noise. It must be realised, however, that since such nebulisers possess a mesh containing ∼4000 identical holes (2–4 μm in diameter), there is great potential for these holes to become blocked or plugged if not cleaned regularly. This, in turn, may result in the need for increased nebulisation time and also a lowered quality of aerosolised drug delivery [5, 6].

It has been reported that although patients are familiar with the importance of nebuliser care, often, the mesh component is never cleaned nor is an appropriate method of disinfection chosen, which in turn will have damaging effects on the mesh [5, 7]. Decreased nebuliser output, increased nebulisation duration and nebulisers prematurely switching off have been reported in a number of studies examining e-Flow Rapid nebuliser evaluation delivering tobramycin over a 6-month period [7, 8]. Due to the fact that the manufacturer's MeshCare system, which involves a reverse rinse of the nebuliser mesh with isotonic saline (5 mL for 20 min) by means of a bespoke small shower head significantly improves nebuliser performance, it is advised to use this system on a monthly basis and particularly when the duration of nebulisation time is increased [8].

Microbial contamination

It has been widely reported that respiratory therapy equipment can become contaminated by Gram-negative bacteria and several outbreaks have been reported with fatal consequences following contamination of disinfected nebulisers with Pseudomonas aeruginosa in patients with COPD [9]. Nebuliser maintenance, cleaning and disinfection are of utmost importance as nebuliser parts, namely the compressor tubing, drug chamber, T-piece and mouthpiece, may be contaminated with both bacteria and fungi (table 2). The diversity of bacteria and fungi that have been found on CF nebulisers is extensive, whereby a total of 35 bacterial genera have been isolated, including 24 genera belonging to Gram-negative bacteria, 10 genera belonging to Gram-positive bacteria and a single genus, Paenibacillus, that is Gram variable. Of concern is the fact that it has been noted that CF patients' devices were positive for clinically significant organisms, namely Burkholderia cenocepacia, Stenotrophomonas maltophilia and P. aeruginosa. Regarding diversity of yeasts and filamentous fungi contaminating CF nebulisers, two genera belonging to the yeasts and 14 genera belonging to the filamentous fungi have been reported. Yeasts and moulds have been reported in high prevalence (57.7%) in nebuliser parts from CF patients even after washing and drying [12, 14].

View this table:
  • View inline
  • View popup
Table 2

Organisms which have been recovered from the nebulisers of patients with CF[10–22]

Most recently, a study from Brazil examined microbial contamination of Pari nebulisers amongst 77 CF patients across seven CF centres in Brazil [14]. All patients within the study were chronically colonised with P. aeruginosa. The study found a variety of pathogenic organisms following cultures obtained from swab samples from the device interface and chamber for nebuliser solution, with the most prevalent being Candida spp. cultured in 71.6% of nebulisers. Remarkably, only 4.8% (six out of 77) of nebulisers cultured nonmucoid P. aeruginosa, which seemed to correlate with the findings on frequency of nebuliser hygiene that was reported to be performed by 97.4% of patients, with cleaning, disinfection and drying being reported by the lesser percentage of 70.3% of patients [14].

Such contaminated nebulisers could potentially result in the deposition of infectious agents beyond the level of the ciliated epithelium, namely in regions of the lung airways that are distal to the terminal bronchioles and, as such, could potentially initiate a pulmonary infection.

Chronic colonisation of P. aeruginosa is a major contributor in the deterioration of lung function in CF, and ultimately associated with the morbidity and mortality of the disease. Prevention of such chronic colonisation and infection is therefore a major goal, and decontaminating nebulisers, which may be a source of this organism, is one important step in such prevention. A study by Pitchford etal. [23] examined contamination of CF patients' home inhalation equipment, and detected P. aeruginosa in respiratory equipment, aerosol masks (20%), nebulisers (17%), medical syringes (10%), connective tubing (6%) and saline solution (4%) from patients who were colonised with this organism. Although an early study, this highlights the important fact that the chain of transmission of P. aeruginosa should be broken, particularly when the first sputum cultures are positive, in order to have a realistic opportunity to eradicate initial acquisition [23].

Experiences of nebuliser hygiene at home

At home

There have been numerous reports of nebuliser hygienic practices in the home that have highlighted that each individual has their own ideas about how to clean and disinfect their nebuliser in terms of frequency of cleaning, washing, drying, disinfection and storage of nebulisers [7, 14, 15, 24]. One of the earliest studies concluded that respiratory therapists should immediately address and improve their nebuliser cleaning methods and replacement practices with more focus on teaching patients these practices [25].

Inpatient stay

Whilst there are various recommendations around nebuliser cleaning at home, primarily from manufacturers' instructions (table S2) and 2013 Infection Prevention and Control (IP&C) Guideline for Cystic Fibrosis commissioned by the CF Foundation (CFF) [26], there is a lack of practical guidelines specific to inpatient nebuliser cleaning and disinfection. The IP&C guidelines recommend the use of single-use disposable nebulisers during hospital admission that, after each use, should be rinsed with sterile water to remove residual volume, the mask/mouthpiece wiped with an alcohol pad and the nebuliser discarded every 24 h [26]. The advice of replacement of single-use nebulisers every 24 h has been challenged by Weber et al. [22], due to the fact that his group observed infrequent contamination of single-patient use nebulisers (0–11%), with only low numbers of epidemiologically important pathogens (<100 colony-forming units) after 24, 48 or 72 h of use [22]. As such, the authors stated that they believed single-use nebulisers could be safely used for up to 72 h before disposal [22].

If reusable nebulisers are used (e.g. home equipment), the CFF-IP&C guideline states after each use, the nebuliser should be cleaned, disinfected, rinsed with sterile water (post-cold water disinfection) and air dried away from the sink. The nebuliser can be reprocessed after each use if this is done according to manufacturer's instructions. This mirrors the recommendations of the Centers for Disease Control and Prevention for inpatient hand-held nebulisers, which are to clean, disinfect, rinse with sterile water (if appropriate) and dry between treatments on the same patient [27].

A recent survey carried out to examine current inpatient nebuliser hygiene practises in the UK [28] reported widespread variation between centres and highlighted everyday challenges. It is of interest to note that it is not common practise in the UK to use single-use disposable nebulisers as advocated by the CFF-IP&C. Such practise is generally reserved for patients who either have forgotten their own nebuliser or do not wish to use their own nebuliser during an inpatient stay. The limited use of such disposable nebulisers may be in part a result of the cost implications. In this study [28], respondents reported nebulisers were washed after use or at least once daily in 90% of cases, but by a variety of methods and washing was carried out by the patient, the carer or a healthcare professional. Disinfection in hospital was performed less frequently, with 33% of respondents reporting nebulisers were never disinfected during an inpatient stay due to lack of either appropriate methods for disinfection or access to decontamination facilities. Indeed, several patients (41%) were required to take their nebuliser components home for disinfection purposes. Air-drying was the most commonly used method for drying the nebuliser but concern was expressed that due to logistical issues, such as small hospital rooms and lack of storage space, many nebulisers were being dried and stored beside splash zones. CF centres should have the appropriate facilities and systems in place to allow washing and disinfecting of nebulisers in a timely fashion to maximise therapy and patient safety.

Evidence-based guidance

Washing procedures

Hand washing

Hand hygiene is considered the most effective tool against hospital-acquired infection, including during decontamination of equipment. A recent study examining whether Staphylococcus aureus dry-surface biofilms may be transferred from contaminated surfaces to healthcare workers' hands showed that these microbes may be further transferred onto multiple surfaces, in sufficient quantities to cause infection, after only one touch of the contaminated item [29]. The CF Trust recommendations insist that good hand hygiene should be practised in all outpatient clinics and all inpatient facilities. Hand washing, disinfection with alcohol rubs or the use of disposable gloves are required before and after contact with each patient [30].

The CFF-IP&C guideline [26] identifies before and after cleaning or disinfecting nebuliser equipment as an important opportunity for hand hygiene by both healthcare professionals and patients or carers, and suggests an alcohol-based hand gel as the preferred method in hospital. Water temperature has been investigated in a small number of studies with regards to hand washing. The updated Association of Perioperative Registered Nurses Recommended Practises for Hand Hygiene (2009) added a new statement to its recommendations that water temperature at the tap should be maintained between 105°F and 120°F (40.64–48.9°C) [31].

Recommendation 1

Healthcare professionals, persons with CF, or carers should wash hands and use hand disinfector gel before and after cleaning and disinfecting the nebuliser. Gloves should be worn by healthcare professionals with hand hygiene performed after removal of gloves.

When to wash nebulisers

A study by de Boer et al. [32] showed that there is a marked difference in concentration of the aerosol cloud and time of nebulisation of tobramycin solution between an unwashed new Pari LC PLUS and one that was washed before use. The new unwashed medication chambers were noted to have large droplet formation on the inner walls, resulting in some of the tobramycin becoming adherent to the walls, and therefore lost to nebulisation.

The manufacturers of the most commonly used and recommended nebulisers in CF all advocate washing the nebulisers after each use (table S2). The CFF-IP&C guidelines concur with this advice for both at-home and hospital inpatient use [26]. O’Malley [33] further clarifies that at home, cleaning should be performed as soon as possible after each use and that if it is not achievable directly after use, then at least to rinse the nebuliser parts well after use to prevent residual medication drying on the device

Recommendation 2

New nebuliser parts should be washed before first use.

Recommendation 3

During inpatient admission and at home, wash the nebuliser parts after each use.

Recommendation 4

Nebulisers should be washed and re-disinfected immediately prior to use after >24 h of inactivity.

Where to wash nebulisers

In the hospital

In a recent survey investigating inpatient nebuliser hygiene practices in the UK, it was noted that many patients used handwashing or bathroom sinks when washing their nebulisers [28]. This is a practice that should be avoided, particularly if the nebuliser parts are not subsequently disinfected, as the presence of clinically relevant microorganisms, such as P.aeruginosa and B. cenocepacia, in hospital sinks and drains has been well documented and in some cases, linked to outbreaks of infection [34, 35]. Possible sources of contamination on CF wards may be from the expectoration of sputum in the sink, the washing of contaminated hands or equipment, such as nebulisers, or the disposal of the water used for cleaning in the sink or toilet. Furthermore, a recent study identified a variety of environmental and clinical genotypes of P. aeruginosa in drains, taps and splash areas around sinks within multiple wards of a hospital, confirming hospital drains as an important source of this organism [36]. Nontuberculous mycobacteria (NTM) are important emerging pathogens in CF and have been reported in 61% of hospital water systems from 21 states within the USA [37]. Water stagnation and the limiting of hot water temperatures to prevent scalds may contribute to biofilm production and provide conditions suitable for mycobacterial growth [38].

Recommendation 5 (inpatient)

During inpatient stay, nebuliser parts should not be washed directly in sinks, especially bathroom sinks. This is particularly important if nebuliser parts are not immediately disinfected after each use. Additionally, nebulisers should not be washed in bathrooms containing a toilet, due to the risk of aerial contamination of the nebuliser by contaminated toilet droplets on flushing.

Recommendation 6 (inpatient)

During inpatient admission, nebuliser parts should be washed in disposable bowls or basins that may be sterilised by autoclaving.

Recommendation 7 (home and inpatient)

Disinfection of nebuliser parts should be performed immediately after washing and these procedures should be performed in the patient's room.

In the home

The presence of P. aeruginosa in households of CF patients has been well documented, and it has been primarily isolated from drains of showers, drainpipes of hand basins in kitchens, bathrooms and drainpipes of toilets [39]. Recently, another study, which examined 11 674 samples taken from a broad range of environmental sites in homes, showed that there was no difference in rates of P. aeruginosa recovery from environmental samples between houses with and without paediatric patients with CF [40]. The exact role of the environment in the acquisition of P. aeruginosa, however, remains unclear. A Belgian study compared the genotypes from newly infected patients with genotypes of isolates from the home environment. Results showed only nine (18%) of the 50 patients in the study had P. aeruginosa genotypes identical to the genotype of the home environment. Environmental samples were obtained from the nebuliser, kitchen, bathroom and toilet, but the majority (72%) of positive samples were recovered from the bathroom. Interestingly, P. aeruginosa was found in only one of the 75 samples taken from the 48 nebulisers of the 50 patients [41]. It must be noted, however, that it has been reported in patients with newly identified CF pathogens that the home environmental strains of Sphingomonas spp. and P. aeruginosa were identical to strains collected from the patients' sputum samples [42]. The existence of other CF pathogens in the home environment has identified not only P. aeruginosa but also Brevibacterium, Enterobacter, Mycobacterium, Neisseria, Staphylococcus and Streptococcus, with sink faucets as sites with the greatest burden of microorganisms [42].

In some guidelines, dishwashers have been recommended to disinfect nebuliser parts [26, 33]. This is not recommended, as studies have confirmed some human opportunistic pathogens are enriched and proliferate inside domestic dishwashers [43]. Exophiala dermatitidis (the “Black Yeast”) is the third most frequently isolated fungus from CF patients, and it has been found on surfaces in kitchens with dishwashers and within dishwashers. Its presence in kitchens without dishwashers, however, is negligible [43]. With increased environmental concerns about energy efficiency and carbon footprint, there is an increasing tendency to operate dishwashers at lower temperatures. Unfortunately, there is no evidence regarding thermal destruction of this organism at dishwasher operating temperatures and, therefore, destruction of this organism cannot be guaranteed.

Given that there are effective alternative thermal disinfection methods available, coupled with the problems of deposition of particulate material on nebulisers undergoing dishwashing, employment of dishwashers is not suitable for either washing or disinfection of devices.

Recommendation 8 (home)

Do not wash nebuliser parts directly in kitchen or bathroom sinks.

Recommendation 9 (home)

Do not wash nebuliser parts in the dishwasher.

Recommendation 10 (home)

Nebuliser parts should be washed in a dedicated plastic, glass or metal bowl in the patient's kitchen. Such bowls should be washed and fully dried between each use.

How to wash nebulisers

Whilst all manufacturers advocate washing nebulisers after each use (table S2), there remain subtle, albeit important, differences in the methods advocated. For example, the water to be used may be described as hot, warm, clean water, tap water or distilled water and it may be recommended to wash, soak for varying time scales or agitate. Soap, detergent or dishwashing liquid may be cited for use. The following section attempts to offer recommendations for each of these differences.

In order to prepare nebulisers for washing, nebulisers should be disconnected from their compressor units and disassembled into their constituent components prior to washing and disinfection. This will allow for improved penetration of water–detergent mixtures to access remote regions of the nebulisers, thereby allowing for improved soil removal. Manufacturers discourage the use of brushes to aid in the washing of aerosol heads as this may cause damage [44].

Recommendation 11

Nebulisers should be disconnected from their compressor units and disassembled into their constituent components prior to washing/disinfection.

Water

It has been reported that nebulisers and masks are significantly more likely to be contaminated if they have been in use for ≥1 month and have only been cleaned by rinsing with tap water after each use [23]. Of further concern is the fact that a study examining the occurrence of P. aeruginosa in water found 8% of tap water tested was positive for this organism, which highlights “the need to disinfect the CF patients’ nebuliser after each use, to maintain an optimal Pseudomonas aeruginosa-free device” [45]. Of note, additional evidence shows that contamination from tap water with P. aeruginosa and B. cenocepacia can be present weeks or years after the resolution of an outbreak [34, 46], most likely due to the formation of biofilms around the organisms that are present in the pipework.

The CFF-IP&C guidelines regarding nebuliser hygiene both during hospitalisation and at home offers advice relating to sources of water, and their use at various stages of nebuliser cleaning and disinfection. The guidance states that tap water or well water that meets local public health standards, distilled water, or bottled water may be used for the cleaning nebulisers if followed by disinfection. Such water sources may be used for heat disinfection. However, they advocate the use of sterile water for use in the final rinse of nebuliser parts, particularly following disinfection [26].

An inpatient study demonstrated the presence of S. maltophilia in hospital taps, potable water and sink drains, highlighting that water may be a potential source of other clinically significant CF organisms [17]. End-line sterilising-grade water filters fitted to taps have been shown to be useful in helping to prevent the transmission of S. maltophilia to nebuliser chambers during washing [47], which may represent a simple, cost-effective practice for nebuliser washing.

There is a lack of scientific evidence available pertaining to the optimum temperature of water specifically for washing nebulisers; however, nebuliser manufacturers generally recommend warm or hot water in their instructions (table S2). A study looking at the cleaning of airway clearance devices showed complete or partial eradication of bacterial yield in 50% and 30%, respectively, of contaminated airway clearance devices when they were soaked for 10 min in hot water (temperature unspecified) and detergent, and rinsed with hot water before air drying [13].

Recommendation 12

Tap water may be used for washing and rinsing nebulisers if it is followed by disinfection. Water should be warm or hot as available and comfortable for the user.

Recommendation 13

Sterile water must be used during a final rinse, when immediate disinfection is not possible. In such cases, this nebuliser should not be treated as disinfected.

Detergent/soap

Employment of detergent is important in order to help the removal of soil associated with the nebuliser. Such soil may include organic and inorganic contaminants, including sputum, saliva and crusted/dried-on nebulised medicines. Detergents act by reducing the surface tension of the liquid used in nebuliser cleaning, as well as promoting the emulsification of oil or grease and holding them in a suspension in water.

Certain protocols, particularly the manufacturers' instructions, cite the use of “soapy water”, whilst others cite “dishwashing liquid” or “liquid detergent”. Overall, there is a lack of standardisation of:

  • terminology surrounding the use of detergent

  • the chemistry of the detergent used

  • detergent concentration

Certain device manufacturers have offered unsupported advice not to use certain detergent types, including those that are pearly and opaque or antibacterial liquid soaps [44], as these may damage the device. Soaps and detergents may themselves be a source of contamination of clinically significant organisms for CF patients [48, 49]. It has also been reported that hand soap dispensing units have been contaminated with Burkholderia cepacia, Pseudomonas putida, P. aeruginosa, Klebsiella pneumoniae, Enterobacter cloacae and Pseudomonas luteola [50].

Recommendation 14

Nebuliser components should be washed in a solution of warm tap water and dishwashing liquid, in accordance with the detergent manufacturer's guidance.

Disposal of used water

As discussed earlier, hospital hand washing sinks and bathroom sinks should not be used for washing nebulisers due to these environments being potential sources of pathogens. The disposal of the water used for cleaning the nebulisers may, in part, contribute to such contamination. Water that has been used in the washing of nebulisers may become contaminated with bacterial pathogens from contaminated nebuliser parts and therefore present a cross-infection risk, particularly within the hospital environment, requiring careful disposal of waste water. Additionally, it has been reported that patients who are infected with P. aeruginosa will excrete this organism in their stools, thereby contaminating the toilet environment [51], which is another potential source of cross infection.

Recommendation 15 (inpatient)

When disposable bowls are used for nebuliser washing, the bowl and waste water should be sent to the ward sluice for disposal. Disposable bowls should not be recycled. Nebuliser waste water should not be disposed of via sinks or toilets in order to prevent cross infection between occupants and subsequent occupants of rooms.

Recommendation 16 (inpatient)

When metal bowls are used for nebuliser washing, the metal bowl and waste water should be sent to the ward sluice. Waste water should be disposed of and the metal bowl should be sterilised by autoclaving.

Recommendation 17 (home)

Given that nebulisers will be washed in a separate container, thereby minimising risk to contaminating household sinks, and given that toilets are likely to be contaminated with the patient's own respiratory organisms, disposal of such waste water should be via the toilet, accompanied by avoidance of inhalation of aerosols by closing of the toilet lid prior to flushing.

Disinfection procedures

Historically, a plethora of methods of disinfection have been used for nebulisers, primarily chemical or thermal in nature; however, it is fundamentally important to ensure that the method used is effective in terms of decontamination and not detrimental to the nebuliser equipment or its output. Chemical and heat disinfection methods that have been used previously are reported in table3. Generally, there are several limitations noted for the chemical disinfection methods, such as limited supporting evidence/preliminary findings, suboptimal methods of disinfection, corrosive activity, safe handling and storage of reagents, and half-life of reagents (table3). Disinfection involving heat is the preferred method for optimal disinfection of nebulisers. Heat disinfection is a physical method and passes through all components of the previously washed/rinsed nebuliser. Employment of heat as a disinfection method is common with all nebuliser manufacturers' instructions, ranging from boiling to autoclaving. Steam disinfection with the aid of “baby bottle steam sterilisers” is an effective method for disinfection of nebuliser devices, as detailed (table 4). Whilst commercially termed a “steriliser” by the CF community and patients, this method is a disinfection method rather than a sterilisation method. This difference in terminology has important microbiological significance as to the anticipated outcome. One of the major advantages of steam disinfection using a baby bottle disinfector unit is that the process is a batch process with terminal (end-stage) disinfection. The sequence of disinfection as the terminal process will allow for the destruction of pathogens detailed in table 4, which may enter during prior stages (tap water, residual sputum, detergent, handling, etc.). Whilst steam disinfection is effective microbiologically in the presence of soil on the nebuliser, it is still important to thoroughly wash nebulisers prior to disinfection, to remove residue that could potentially interfere with the optimal performance of the device.

View this table:
  • View inline
  • View popup
Table 3

A list of documented methods used to disinfect nebulisers

View this table:
  • View inline
  • View popup
Table 4

Advantages and disadvantages of steam disinfection for nebuliser devices

Recommendation 18 (home and inpatient)

Washed and rinsed nebulisers should be disinfected after each use by employment of heat using an electric baby bottle steam disinfector, in accordance with the manufacturer's instructions.

Recommendation 19 (inpatient)

Reusable nebulisers may be autoclaved where the nebuliser manufacturer states that the device can be safely autoclaved.

Drying

Desiccation (drying) is a technique that can be used to effectively kill bacteria [70]. In theory, air drying the nebuliser should significantly reduce the risk of nosocomial infection. In the study by Manor et al. [13], simple cleaning and air drying without disinfection was found to be effective in most cases. Air drying has been advocated as a method of drying to cause least recontamination of cleaned parts [62] and is now the drying technique of choice advocated by many nebuliser manufacturers.

A recent study by Moore et al. [71] examined the effect of drying on P. aeruginosa and showed that there were marked differences in time to complete dryness between disassembled and fully assembled nebulisers. Vigorous repeated shaking was unable to drive off all residual water on assembled nebulisers. P. aeruginosa counts did not decrease significantly in either tap water or in tap water plus detergent after 24 h storage at ambient temperature. In contrast, all Pseudomonas organisms were killed when dried for 24 h, even when contaminated with 1% and 10% sputum. Dishwashing detergent did not demonstrate any antibacterial activity. The study concluded that drying of the nebuliser, if applied properly, can reduce counts of P. aeruginosa to undetectable levels and therefore minimise risk of acquisition of P. aeruginosa in the patient from the nebuliser device. Equally, this study showed that if the device is not dried thoroughly and moisture remains, then the device is able to support the survival of P. aeruginosa at high numbers, constituting an infection risk to the CF patient. These data may help educate and inform the CF patient about the importance of proper nebuliser drying for Pseudomonas control, in order to improve patient awareness and safety [71]. More recently, there have been two reports demonstrating that members of the NTM, Mycobacterium abscessus complex and S. aureus (methicillin-sensitive and -resistant) can survive for at least 24 h on plastic surfaces during air drying [72, 73]. Therefore, whilst drying may be advantageous for nebuliser performance, it should not be regarded as an absolute critical control for the elimination of NTM or S. aureus organisms on nebuliser devices and, hence, devices should be disinfected with heat in accordance with recommendations 18 and 19.

As highlighted in previous sections, care must be taken to ensure that parts that are left out to air dry are kept away from sinks and potential splash areas [36], which in itself may pose a logistical problem in a small hospital room with limited surfaces. Enough time must be given to allow the parts to dry fully, which may be challenging during an inpatient admission when nebulised therapies and airway clearance are being optimised. In addition, some components are difficult to dry and the degree of dryness can be difficult to assess.

The use of disposable paper towels for active drying was shown as the next best alternative, with a low count of bacteria detected [62]. However, use of paper towels may cause decreased performance of some nebulisers by clogging of pores (such as the Eflow aerosol head) and as such, is not recommended by certain manufacturers.

The study by Hohenwarter et al. [62] has challenged whether drying is necessary after steam disinfection, as they reported that nebulisers that were disinfected and left undisturbed in a baby bottle disinfector remained bacteria free until the next use within 24 h. They suggest that this may be a better solution as they have shown that active drying may cause recontamination. In addition, the authors suggest that this would be a simple, effective and time-efficient method for patients and carers to adopt.

Storage

The storage of disinfected nebuliser parts in a sealed disinfector unit after the cycle has finished [62] removes the risk of re-contaminating an already disinfected device, as well as avoiding the need for additional storage space.

It is vital that even though a disinfection method may be presumed to be effective, that instruction for storage of disinfected nebulisers is also given, as storage of damp nebulisers is a potential source of contamination [9]. A recent study [74] examined the microbiology of plastic disposal boxes that were used to store washed nebulisers and found that 80% of patients had at least one of their storage boxes positive for bacteria. Overall, 83% (20 out of 24) of boxes were positive for bacteria; however, the majority of these (65%) had a contamination rate of <103 colony forming units (cfu) per box. 15% of positive boxes were contaminated with 103–104 cfu per box, with the remainder (20%) contaminated with between 104 and 105 cfu per box. The most highly contaminated box harboured 5.4×104 cfu. Bacterial diversity demonstrated a predominately Gram-positive flora, representing 15 genera and 22 species. Micrococccus luteus and Dermacoccus nishinomiyaensis were the most commonly isolated species, with coagulase-negative staphylococci and the viridans group (oral) streptococci having the greatest species diversity within their respective genera. Gram-negative bacteria were in the minority, representing 8.3% of bacterial species isolated, namely S. maltophilia and Neisseria flava/perflava/subflava. Fungi were isolated from four (26.7%) out of 15 boxes and included Penicillium sp., Penicillium expansum, Cladosporium sp. and Candida albicans.

Recommendation 20: (home and inpatient)

Following disinfection in a baby bottle steam disinfector, nebuliser parts should be left undisturbed in the disinfector until the next use (within 24 h). Should the parts be disturbed (i.e. the lid lifted off for any reason), then the disinfection process should be repeated and the parts left undisturbed until the next use (within 24 h).

Wash hands thoroughly with soap and water, and use hand disinfector gel after the cleaning and disinfection processes, prior to reassembling the nebuliser device (recommendation 1).

Barriers and motivators related to nebuliser hygiene

The absence of universal guidance relating to nebuliser care and hygiene appear to have contributed to the current situation where CF patients are bereft of vital knowledge on the importance of such practices. These practices should be an essential component of their routine CF treatment regime. The customary information-giving process alone may not be enough to assist CF patients and families in implementing and maintaining long-term behavioural change. In the dissemination of universal guidance, it is crucial that the education of staff, patients and families isa priority. The guidance should be clear, consistent, systematic and predicated on an understanding of the complexity of the CF treatment regimen and, in particular, the heavy time burden on patients.

It is important that there is a process of ongoing monitoring of the implementation as well as routine assessment of the barriers and motivators to implementation as experienced by staff, patients and families. Collaborative adherence promotion interventions developed by CF healthcare professionals have the potential to advance clinical practice [75]. The focus should be on developing ways to overcome the barriers and use motivators to ensure that nebuliser care and hygiene becomes an established part of the daily treatment routine of the CF patient. The clinical outcomes of the new nebuliser care procedures need to be fed back to staff, patients and families to elucidate the impact of adherent behaviour on the health of CF patients.

We can gain inspiration from Luby et al. [76], who studied the effect of hand washing on child health in Karachi, Pakistan. They made soap use more systematic in people living in the slums of Karachi. The soap distribution led to behaviour change as fieldworkers provided people with soap and specific instruction on hand washing technique and hygiene practices. The decreased incidence of diarrhoea, impetigo and pneumonia demonstrates the effectiveness of this intervention. In a 5-year follow up, there were sustained improvements in handwashing indicators [77]. They attributed the sustained behavioural change to the intensive nature of the intervention and the habituation of handwashing behaviour until it acquired a degree of unconscious automaticity.

Similarly, a study carried out by a group in Brazil successfully showed that an educational programme had a significant positive outcome on nebuliser contamination [21].

The inpatient setting provides an opportunity for re-education of appropriate cleaning and disinfecting standards to enable patient ownership of their healthcare. It is therefore imperative for healthcare professionals responsible for endorsing cleaning and disinfecting methods, to be able to follow the gold-standard care themselves. Lack of clarity and differing advice may discourage the CF patient and/or carer from engaging with the importance of nebuliser care.

Conclusions

Nebuliser therapy constitutes one small part of the daily treatment burden for people living with CF and therefore, the maintenance and hygiene of the nebuliser itself can often be overlooked as an essential aspect of this daily care. As well as promoting the importance of taking prescribed nebuliser treatments, emphasis should equally be placed on the importance of nebuliser care to patients' outcomes, as being pivotal in preventing reinfection, optimising delivery of treatment safely and efficiently, thus ensuring maximum benefit and reduced risk in using nebulisers. Confusion as a result of differing manufacturers' advice, lack of clear guidelines and conflicting anecdotal advice from caregivers may have a negative impact on adherence to nebuliser care.

This review has presented the current evidence base to rationalise the need for nebuliser hygiene and to present evidence-based recommendations (figure 1 and table 5), which can be used to help guide local nebuliser infection control policy.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Summary of recommendations as a flow diagram.

View this table:
  • View inline
  • View popup
Table 5

Summary of evidence-based best practice guidelines relating to nebuliser hygiene in CF

Appropriate care and maintenance of the nebuliser must form an integral part of the education and behavioural change programme when commencing nebuliser therapy and this must be re-asserted alongside the reassessment of nebuliser inhalation technique and usage.

The Northern Ireland Working Group on Nebuliser Care and Hygiene in Cystic Fibrosis has produced two YouTube videos to accompany this article.

  • Nebuliser cleaning & hygiene in cystic fibrosis: https://youtu.be/-b4hXUuRiFo

  • Cleaning the nebuliser (for children): https://youtu.be/Pw_w9ZXrHsw

Key points

  • Nebuliser hygiene is essential to ensure optimal performance of the device as well as being a vital step to avoid microbial contamination of the components and potential infection/re-infection to the user.

  • Current nebuliser hygiene practice is varied and challenging, both at home and during inpatient stays.

  • Consideration must be given to the location, timing and procedure for washing, disinfecting and drying nebuliser components.

  • Education of patients, families and staff is essential to drive long term adherence to nebuliser hygiene guidelines.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Figure S1 EDU-0328-2019.figureS1

Table S1 EDU-0328-2019.tableS1

Table S2 EDU-0328-2019.tableS2

Acknowledgements

This review was guided by the Northern Ireland Working Group on Nebuliser Care and Hygiene in Cystic Fibrosis. The authors were members of the working group and were involved in meeting and planning of the review, as well as examination of the evidence-based literature. All authors contributed to writing the manuscript. The other members of the working group were involved in meeting and planning of the review: Niju Baby, Catherine Bell, Kevin Brookfield, Lesley Carson, Colin Goldsmith, Julie Hanna, Katherine Lavery, Lisa Murphy, Mary Macfarlane, Valerie Mills, Liz Quinn. All members of the working group reviewed, edited and approved the final version of the manuscript. The views, opinions, findings, conclusions and recommendations set forth in this manuscript are solely those of the authors and do not necessarily reflect the views, policy or position of the affiliations of the authors.

Footnotes

  • This article has supplementary material available from breathe.ersjournals.com.

  • Support statementThe Northern Ireland Working Group on Nebuliser Care and Hygiene in Cystic Fibrosis is supported by an unrestricted medical educational grant from Vertex Pharmaceuticals Inc., Boston, MA, USA.

  • Conflict of interest: J. Bell has nothing to disclose.

  • Conflict of interest: L. Alexander has nothing to disclose.

  • Conflict of interest: J. Carson has nothing to disclose.

  • Conflict of interest: A. Crossan reports speaker honoraria from TEVA and AstraZeneca, and sponsorship to attend a European cystic fibrosis conference from Chiesi, all outside the submitted work.

  • Conflict of interest: J. McCaughan has nothing to disclose.

  • Conflict of interest: H. Mills has nothing to disclose.

  • Conflict of interest: D. O'Neill has nothing to disclose.

  • Conflict of interest: J.E. Moore has nothing to disclose.

  • Conflict of interest: B.C. Millar has nothing to disclose.

  • Received November 12, 2019.
  • Accepted April 7, 2020.
  • Copyright ©ERS 2020
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Agent P,
    2. Parrott H
    . Inhaled therapy in cystic fibrosis: agents, devices and regimens. Breathe 2015; 11: 110–118. doi:10.1183/20734735.021014
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Heijerman H,
    2. Westerman E,
    3. Conway S, et al.
    Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros 2009; 8: 295–315. doi:10.1016/j.jcf.2009.04.005
    OpenUrlCrossRefPubMed
  3. ↵
    1. Boe J,
    2. Dennis J,
    3. O'Driscoll B, et al.
    European Respiratory Society guidelines on the use of nebulizers. Eur Respir J 2001; 18: 228–242. doi:10.1183/09031936.01.00220001
    OpenUrlFREE Full Text
  4. ↵
    1. Pasteur M,
    2. Bilton D,
    3. Hill A
    . British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: i1–i58. doi:10.1136/thx.2010.136119
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Baravalle-Einaudi M,
    2. Dufeu N,
    3. Dupont C, et al.
    Vibrating-mesh nebulizer maintenance by CF patients: results from a French survey. Pulm Pharmacol Ther 2017; 44: 57–60. doi:10.1016/j.pupt.2017.03.011
    OpenUrl
  6. ↵
    1. Rottier BL,
    2. van Erp CJ,
    3. Sluyter TS, et al.
    Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv 2009; 22: 263–269. doi:10.1089/jamp.2008.0712
    OpenUrlCrossRefPubMed
  7. ↵
    1. Reychler G,
    2. Bosschaerts M,
    3. Chevaillier J, et al.
    Inhalation equipment hygiene: a Belgian national survey. J Aerosol Med Pulm Drug Deliv 2009; 22: 239–243. doi:10.1089/jamp.2008.0722
    OpenUrlPubMed
  8. ↵
    1. Le Pennec D,
    2. Baravalle-Einaudi M,
    3. Dupont C, et al.
    Cystic fibrosis in the modern therapeutic era: Give the shower a thought! J Cyst Fibros 2019; 18: e56–e57. doi:10.1016/j.jcf.2019.03.004
    OpenUrl
  9. ↵
    1. Cobben NA,
    2. Drent M,
    3. Jonkers M, et al.
    Outbreak of severe Pseudomonas aeruginosa respiratory infections due to contaminated nebulizers. J Hosp Infect 1996; 33: 63–70. doi:10.1016/S0195-6701(96)90030-4
    OpenUrlCrossRefPubMed
    1. Hutchinson GR,
    2. Parker S,
    3. Pryor JA, et al.
    Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol 1996; 34: 584–587. doi:10.1128/JCM.34.3.584-587.1996
    OpenUrlAbstract/FREE Full Text
    1. Blau H,
    2. Mussaffi H,
    3. Mei Zahav M, et al.
    Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev 2007; 33: 491–495. doi:10.1111/j.1365-2214.2006.00669.x
    OpenUrlCrossRefPubMed
  10. ↵
    1. Peckham D,
    2. Williams K,
    3. Wynne S, et al.
    Fungal contamination of nebuliser devices used by people with cystic fibrosis. J Cyst Fibros 2016; 15: 74–77. doi:10.1016/j.jcf.2015.06.004
    OpenUrl
  11. ↵
    1. Manor E,
    2. Gur M,
    3. Geffen Y, et al.
    Cleaning and infection control of airway clearance devices used by CF patients. Chron Respir Dis 2017; 14: 370–376. doi:10.1177/1479972317707652
    OpenUrl
  12. ↵
    1. Riquena B,
    2. Monte LFV,
    3. Lopes AJ, et al.
    Microbiological contamination of nebulizers used by cystic fibrosis patients: an underestimated problem. J Bras Pneumol 2019; 45: e20170351. doi:10.1590/1806-3713/e20170351
    OpenUrl
  13. ↵
    1. Murray TS,
    2. O'Rourke TK Jr.,
    3. Feinn R, et al.
    Nebulizer cleaning and disinfection practices in families with cystic fibrosis: The relationship between attitudes, practice and microbe colonization. J Cyst Fibros 2019; 18: 823–828. doi:10.1016/j.jcf.2019.05.008
    OpenUrl
    1. O'Malley CA,
    2. VandenBranden SL,
    3. Zheng XT, et al.
    A day in the life of a nebulizer: surveillance for bacterial growth in nebulizer equipment of children with cystic fibrosis in the hospital setting. Respir Care 2007; 52: 258–262.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Denton M,
    2. Rajgopal A,
    3. Mooney L, et al.
    Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis. J Hosp Infect 2003; 55: 180–183. doi:10.1016/S0195-6701(03)00299-8
    OpenUrlCrossRefPubMed
    1. Jakobsson BM,
    2. Onnered AB,
    3. Hjelte L, et al.
    Low bacterial contamination of nebulizers in home treatment of cystic fibrosis patients. J Hosp Infect 1997; 36: 201–207. doi:10.1016/S0195-6701(97)90195-X
    OpenUrlCrossRefPubMed
    1. Vassal S,
    2. Taamma R,
    3. Marty N, et al.
    Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control 2000; 28: 347–351. doi:10.1067/mic.2000.110214
    OpenUrlCrossRefPubMed
    1. Brzezinski LX,
    2. Riedi CA,
    3. Kussek P, et al.
    Nebulizers in cystic fibrosis: a source of bacterial contamination in cystic fibrosis patients? J Bras Pneumol 2011; 37: 341–347. doi:10.1590/S1806-37132011000300010
    OpenUrlPubMed
  15. ↵
    1. Della Zuana A,
    2. Garcia Dde O,
    3. Juliani RC, et al.
    Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers. J Bras Pneumol 2014; 40: 119–127. doi:10.1590/S1806-37132014000200004
    OpenUrl
  16. ↵
    1. Weber DJ,
    2. Gergen MF,
    3. Sickbert-Bennett EE, et al.
    Frequency of contamination of single-patient-use nebulizers over time. Infect Control Hosp Epidemiol 2014; 35: 1543–1546. doi:10.1086/678603
    OpenUrl
  17. ↵
    1. Pitchford KC,
    2. Corey M,
    3. Highsmith AK, et al.
    Pseudomonas species contamination of cystic fibrosis patients’ home inhalation equipment. Pediatr 1987; 111: 212–216. doi:10.1016/S0022-3476(87)80069-0
    OpenUrl
  18. ↵
    1. MacFarlane M,
    2. Carson L,
    3. Crossan A, et al.
    Nebuliser cleaning and disinfection practice in the home among patients with cystic fibrosis. J Infec Prev 2020; 21: 14–22. doi:10.1177/1757177419855603
    OpenUrl
  19. ↵
    1. O'Malley CA
    . Infection control in cystic fibrosis: cohorting, cross-contamination and the respiratory therapist. Respir Care 2009; 54: 641–655. doi:10.4187/aarc0446
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Saiman L,
    2. Siegel JD,
    3. LiPuma JJ, et al.
    Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014; 35: Suppl. 1, 1–67. doi:10.1086/676882
    OpenUrl
  21. ↵
    1. Tablan OC,
    2. Anderson LJ,
    3. Besser R, et al.
    Guidelines for preventing health-care–associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004; 53: 1–36.
    OpenUrlPubMed
  22. ↵
    1. Bell J,
    2. Moore JE,
    3. Millar BC
    . Cleaning of inpatient nebulizer devices in cystic fibrosis patients: the urgent need for universal guidelines. J Hosp Infect 2018; 100: e64–e66. doi:10.1016/j.jhin.2018.06.025
    OpenUrl
  23. ↵
    1. Chowdhury D,
    2. Tahir S,
    3. Legge M, et al.
    Transfer of dry surface biofilm in the healthcare environment: the role of healthcare workers’ hands as vehicles. J Hosp Infect 2018; 100: e85–e90. doi:10.1016/j.jhin.2018.06.021
    OpenUrl
  24. ↵
    1. Cystic Fibrosis Trust
    . Consensus documents. www.cysticfibrosis.org.uk/the-work-we-do/resources-for-cf-professionals/consensus-documents.
  25. ↵
    1. Patrick M,
    2. van Wicklin SA
    . Implementing AORN recommended practices for hand hygiene. AORN 2012; 95: 492–504. doi:10.1016/j.aorn.2012.01.019
    OpenUrl
  26. ↵
    1. de Boer AH,
    2. Hagedoorn P,
    3. Frijlink HW
    . The choice of a compressor for the aerosolization of tobramycin (TOBI®) with the PARI LC PLUS® reusable nebuliser. I J Pharm 2003; 268: 59–69.
    OpenUrl
  27. ↵
    1. O'Malley CA
    . Device cleaning and infection control in aerosol therapy. Respir Care 2015; 60: 917–931. doi:10.4187/respcare.03513
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Bédard E,
    2. Laferrière C,
    3. Charron D, et al.
    Post-outbreak investigation of Pseudomonas aeruginosa faucet contamination by quantitative polymerase chain reaction and environmental factors affecting positivity. Infect Control Hosp Epidemiol 2015; 36: 1337–1343. doi:10.1017/ice.2015.168
    OpenUrl
  29. ↵
    1. Lucero CA,
    2. Cohen AL,
    3. Trevino I, et al.
    Outbreak of Burkholderia cepacia complex among ventilated patients linked to hospital sinks. Am J Infect Control 2011; 39: 775–778. doi:10.1016/j.ajic.2010.12.005
    OpenUrlCrossRefPubMed
  30. ↵
    1. Lalancette C,
    2. Charron D,
    3. Laferrière C, et al.
    Hospital drains as reservoirs of Pseudomonas aeruginosa: Multiple-locus variable-number of tandem repeats analysis genotypes recovered from faucets, sink surfaces and patients. Pathogens 2017; 6: E36. doi:10.3390/pathogens6030036
    OpenUrlCrossRef
  31. ↵
    1. Covert TC,
    2. Rodgers MR,
    3. Reyes AL, et al.
    Occurrence of nontuberculous mycobacteria in environmental samples. Appl Environ Microbiol 1999; 65: 2492–2496. doi:10.1128/AEM.65.6.2492-2496.1999
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Wallace RJ Jr.,
    2. Brown BA,
    3. Griffith DE
    . Nosocomial outbreaks/pseudo-outbreaks caused by nontuberculous mycobacteria. Annu Rev Microbiol 1998; 52: 453–490. doi:10.1146/annurev.micro.52.1.453
    OpenUrlCrossRefPubMed
  33. ↵
    1. Regnath T,
    2. Kreutzberger M,
    3. Illing S, et al.
    Prevalence of Pseudomonas aeruginosa in households of patients with cystic fibrosis. Int J Hyg Environ Health 2004; 207: 585–588. doi:10.1078/1438-4639-00331
    OpenUrlCrossRefPubMed
  34. ↵
    1. Purdy-Gibson ME,
    2. France M,
    3. Hundley TC, et al.
    Pseudomonas aeruginosa in CF and non-CF homes is found predominantly in drains. J Cyst Fibros 2015; 14: 341–346. doi:10.1016/j.jcf.2014.10.008
    OpenUrlCrossRef
  35. ↵
    1. Schelstraete P,
    2. Van Daele S,
    3. De Boeck K, et al.
    Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients. Eur Respir J 2008; 31: 822–829. doi:10.1183/09031936.00088907
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Heirali A,
    2. McKeon S,
    3. Purighalla S, et al.
    Assessment of the microbial constituents of the home environment of individuals with cystic fibrosis (CF) and their association with lower airways infections. PLoS One 2016; 11: e0148534. doi:10.1371/journal.pone.0148534
    OpenUrlCrossRef
  37. ↵
    1. Zupančič J,
    2. Novak Babič M,
    3. Zalar P, et al.
    The black yeast Exophiala dermatitidis and other selected opportunistic human fungal pathogens spread from dishwashers to kitchens. PLoS One 2016; 11: e0148166. doi:10.1371/journal.pone.0148166
    OpenUrlCrossRef
  38. ↵
    1. Cayston
    . Cleaning and disinfecting. https://www.cayston.com/dosing/cleaning-and-disinfecting.
  39. ↵
    1. Caskey S,
    2. Stirling J,
    3. Moore JE, et al.
    Occurrence of Pseudomonas aeruginosa in waters: implications for patients with cystic fibrosis (CF). Lett Appl Microbiol 2018; 66: 537–541. doi:10.1111/lam.12876
    OpenUrl
  40. ↵
    1. Moore JE,
    2. Thompson I,
    3. Crowe M, et al.
    Burkholderia cepacia from a sink drain. J Hosp Infect 2002; 50: 235–237. doi:10.1053/jhin.2001.1175
    OpenUrlCrossRefPubMed
  41. ↵
    1. Woodhouse R,
    2. Peckham DG,
    3. Conway SP, et al.
    Water filters can prevent Stenotrophomonas maltophilia contamination of nebuliser equipment used by people with cystic fibrosis. J Hosp Infect 2008; 68: 371–372. doi:10.1016/j.jhin.2008.01.004
    OpenUrlPubMed
  42. ↵
    1. Blanc DS,
    2. Gomes Magalhaes B,
    3. Abdelbary M, et al.
    Hand soap contamination by Pseudomonas aeruginosa in a tertiary care hospital: no evidence of impact on patients. J Hosp Infect 2016; 93: 63–67. doi:10.1016/j.jhin.2016.02.010
    OpenUrl
  43. ↵
    1. Zimakoff J,
    2. Høiby N,
    3. Rosendal K, et al.
    Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect 1983; 4: 31–40. doi:10.1016/0195-6701(83)90062-2
    OpenUrlCrossRefPubMed
  44. ↵
    1. Caetano JA,
    2. Lima MA,
    3. Di Ciero Miranda M, et al.
    Identification of bacterial contamination in liquid soap for hospital use. Rev Esc Enferm USP 2011; 45: 153–160. doi:10.1590/S0080-62342011000100021
    OpenUrlPubMed
  45. ↵
    1. Döring G,
    2. Bareth H,
    3. Gairing A, et al.
    Genotyping of Pseudomonas aeruginosa sputum and stool isolates from cystic fibrosis patients: evidence for intestinal colonization and spreading into toilets. Epidemiol Infect 1989; 103: 555–564. doi:10.1017/S0950268800030958
    OpenUrlPubMed
    1. Reychler G,
    2. Aarab K,
    3. Van Ossel C, et al.
    In vitro evaluation of efficacy of 5 methods of disinfection on mouthpieces and facemasks contaminated by strains of cystic fibrosis patients. J Cyst Fibros 2005; 4: 183–187. doi:10.1016/j.jcf.2005.06.001
    OpenUrlCrossRefPubMed
    1. Jadhav S,
    2. Sahasrabudhe T,
    3. Kalley V, et al.
    The microbial colonization profile of respiratory devices and the significance of the role of disinfection: a blinded study. J Clin Diagn Res 2013; 7: 1021–1026.
    OpenUrl
    1. Caskey S,
    2. Moore JE,
    3. Rendall JC
    . In vitro activity of seven hospital biocides against Mycobacterium abscessus: Implications for patients with cystic fibrosis. Int J Mycobacteriol 2018; 7: 45–47. doi:10.4103/ijmy.ijmy_197_17
    OpenUrl
    1. Collins MS,
    2. O'Brien M,
    3. Schramm CM, et al.
    Repeated hot water and steam disinfection of Pari LC Plus® nebulizers alter nebulizer output. J Cyst Fibros 2019; 18: 233–235. doi:10.1016/j.jcf.2018.08.005
    OpenUrl
    1. Reychler G,
    2. Leonard A,
    3. Van Ossel C, et al.
    Impact of hypochlorite-based disinfection on bacterial contamination of cystic fibrosis patients’ home-nebulisers. J Hosp Infect 2009; 72: 351–357. doi:10.1016/j.jhin.2009.05.011
    OpenUrlCrossRefPubMed
    1. Towle D,
    2. Baker V,
    3. Schramm C, et al.
    Ozone disinfection of home nebulizers effectively kills common cystic fibrosis bacterial pathogens. Pediatr Pulmonol 2018; 53: 599–604. doi:10.1002/ppul.23990
    OpenUrl
    1. Djouhri-Bouktab L,
    2. Alhanout K,
    3. Andrieu V, et al.
    Soluble squalamine tablets for the rapid disinfection of home nebulizers of cystic fibrosis patients. J Cyst Fibros 2012; 11: 555–559. doi:10.1016/j.jcf.2012.05.006
    OpenUrlPubMed
    1. Millar BC,
    2. Bell J
    . Comment on “repeated hot water and steam disinfection of pari LC Plus® nebulizers alter nebulizer output”. J Cyst Fibros 2019; 18: e16. doi:10.1016/j.jcf.2018.12.012
    OpenUrl
    1. Towle D,
    2. Callan DA,
    3. Farrel PA, et al.
    Baby bottle steam sterilizers disinfect home nebulizers inoculated with bacterial respiratory pathogens. J Cyst Fibros 2013; 12: 512–516. doi:10.1016/j.jcf.2012.11.013
    OpenUrl
    1. Towle D,
    2. Callan DA,
    3. Lamprea C, et al.
    Baby bottle steam sterilizers for disinfecting home nebulizers inoculated with non-tuberculous mycobacteria. J Hosp Infect 2016; 92: 222–225. doi:10.1016/j.jhin.2015.08.030
    OpenUrl
  46. ↵
    1. Hohenwarter K,
    2. Prammer W,
    3. Aichinger W, et al.
    An evaluation of different steam disinfection protocols for cystic fibrosis nebulizers. J Cyst Fibros 2016; 15: 78–84. doi:10.1016/j.jcf.2015.07.005
    OpenUrl
    1. Wabi Baby
    . Sterilization and drying should always go hand in hand. https://wabibaby.zendesk.com/hc/en-us/article_attachments/115001439312/Test-Article.pdf.
    1. Bakuridze L,
    2. Andrieu V,
    3. Dupont C, et al.
    Does repeated disinfection of the e-Flow rapid nebulizer affect in vitro performance? J Cyst Fibros 2007; 6: 309–310. doi:10.1016/j.jcf.2006.12.008
    OpenUrlCrossRefPubMed
    1. Rosaspina S,
    2. Salvatorelli G,
    3. Anzanel D
    . The bactericidal effect of microwaves on Mycobacterium bovis dried on scalpel blades. J Hosp Infect 1994; 26: 45–50. doi:10.1016/0195-6701(94)90078-7
    OpenUrlCrossRefPubMed
    1. Rosaspina S,
    2. Salvatorelli G,
    3. Anzanel D, et al.
    Effect of microwave radiation on Candida albicans. Microbios 1994; 78: 55–59.
    OpenUrlPubMed
    1. Sanborn MR,
    2. Wan SK,
    3. Bulard R
    . Microwave sterilization of plastic tissue culture vessels for reuse. Appl Environ Microbiol 1982; 44: 960–964. doi:10.1128/AEM.44.4.960-964.1982
    OpenUrlAbstract/FREE Full Text
    1. Le Brun PPH,
    2. Brimicombe RW,
    3. van Doorne H, et al.
    The cleaning and disinfection of nebulizers used at home and in a cystic fibrosis centre. Eur Hosp Pharm 2000; 6: 58–63.
    OpenUrl
    1. Pari
    . Cleaning and maintenance. https://www.pari.com/us-en/education-ceu/cleaning-maintenance/.
  47. ↵
    1. Potts M
    . Desiccation tolerance of prokaryotes. Microbiol Rev 1994; 58: 755–805. doi:10.1128/MMBR.58.4.755-805.1994
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Moore JE,
    2. Moore RE,
    3. Bell J, et al.
    Importance of nebulizer drying for patients with cystic fibrosis. Respir Care 2020: respcare.07362. doi:10.4187/respcare.07362
  49. ↵
    1. Moore JE,
    2. Millar BC
    . Susceptibility of the Mycobacterium abscessus complex to drying: implications for nebulizer hygiene in patients with cystic fibrosis. Int J Mycobacteriol 2020; 9: 173–175. doi:10.4103/ijmy.ijmy_62_20
    OpenUrl
  50. ↵
    1. Moore JE,
    2. Millar BC
    . Susceptibility of Staphylococcus aureus (MSSA and MRSA) to drying: implications for nebulizer hygiene in patients with cystic fibrosis. J Hosp Infect 2020; 105: 366–368. doi:10.1016/j.jhin.2020.04.015
    OpenUrl
  51. ↵
    1. Alexander L,
    2. Carson J,
    3. McCaughan J, et al.
    Thinking inside the box – nebuliser care, safe storage and risk of infection. J Bras Pneumol 2020; 46: e20190226.
    OpenUrl
  52. ↵
    1. Rohan JM,
    2. Drotar D,
    3. Perry AR, et al.
    Training health care providers to conduct adherence promotion in pediatric settings: an example with pediatric asthma. Clin Pract Pediatr Psychol 2013; 1: 314–325. doi:10.1037/cpp0000036
    OpenUrl
  53. ↵
    1. Luby SP,
    2. Agboatwalla M,
    3. Feikin D, et al.
    Effect of handwashing on child health: a randomized controlled trial. Lancet 2005; 366: 225–233. doi:10.1016/S0140-6736(05)66912-7
    OpenUrlCrossRefPubMed
  54. ↵
    1. Bowen A,
    2. Agboatwalla M,
    3. Ayers T, et al.
    Sustained Improvements in Handwashing Indicators more than 5 years after a cluster-randomised, community-based trial of handwashing promotion in Karachi, Pakistan. Trop Med Int Health 2013; 18: 259–267.
    OpenUrlPubMed
PreviousNext
Back to top
Vol 16 Issue 2 Table of Contents
Breathe: 16 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nebuliser hygiene in cystic fibrosis: evidence-based recommendations
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Nebuliser hygiene in cystic fibrosis: evidence-based recommendations
Jane Bell, Lauren Alexander, Jane Carson, Amanda Crossan, John McCaughan, Hazel Mills, Damian O'Neill, John E. Moore, B. Cherie Millar
Breathe Jun 2020, 16 (2) 190328; DOI: 10.1183/20734735.0328-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Nebuliser hygiene in cystic fibrosis: evidence-based recommendations
Jane Bell, Lauren Alexander, Jane Carson, Amanda Crossan, John McCaughan, Hazel Mills, Damian O'Neill, John E. Moore, B. Cherie Millar
Breathe Jun 2020, 16 (2) 190328; DOI: 10.1183/20734735.0328-2019
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Sources of information
    • Definitions of key terms
    • Why is there a need to clean and disinfect nebulisers?
    • Experiences of nebuliser hygiene at home
    • Evidence-based guidance
    • Disposal of used water
    • Disinfection procedures
    • Drying
    • Storage
    • Barriers and motivators related to nebuliser hygiene
    • Conclusions
    • Supplementary material
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Management of difficult-to-treat asthma in adolescence and young adults
  • Respiratory complications of obesity
  • Diagnosis and management of PH in infants with BPD
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society